SCHEMBL10134753

SCHEMBL10134753

N#Cc1ccc2c(c1)nc(Nc1ccc(F)cc1)c1cscc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 7/20 0.43
CDC7 O00311 1/20 0.43
CTNNB1 P35222 1/20 0.42
TCF7L2 Q9NQB0 1/20 0.42
CYP1A2 P05177 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
HSD17B10 Q99714 1/20 0.41
CSNK2A1 P68400 5/20 0.41
SYK P43405 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
USP2 O75604 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10134757 0.89 CSNK2A1 (0.42) ABCG2CYP1A2KDM4EMEN1ALDH1A1
SCHEMBL10134770 0.87 CSNK2A1 (0.45) ABCG2CYP1A2KDM4EMEN1ALDH1A1
SCHEMBL10134763 0.86 CSNK2A1 (0.46) ABCG2CSNK2A1CSNK2A2CSNK2B
SCHEMBL13688023 0.82 CSNK2A1 (0.44) ABCG2MEN1TP53MAPTKMT2A
SCHEMBL10134755 0.81 CSNK2A1 (0.45) ABCG2KDM4EMEN1KMT2ACSNK2A1
SCHEMBL10134767 0.81 TDO2 (0.49) ABCG2TP53MAPTTSHRCSNK2A1
SCHEMBL10134817 0.77 CSNK2A1 (0.68) CSNK2A1CSNK2A2CSNK2B
SCHEMBL10135169 0.75 CSNK2A1 (0.59) ABCG2CYP1A2KDM4EMEN1ALDH1A1
SCHEMBL10134833 0.74 CSNK2A1 (0.56) ABCG2CTNNB1TCF7L2KDM4EMEN1
SCHEMBL10134739 0.73 KMT2A (0.36) KDM4EALDH1A1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-20120208792-A1 PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2012-08-16 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-8168651-B2 Protein kinase modulators CYLENE PHARMACEUTICALS, INC. (US) 2012-05-01 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed
US-20090239859-A1 PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208792-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 ABCG2 2980/4885CDC7 141/4885CTNNB1 4214/4885
US-20090239859-A1 PROTEIN KINASE MODULATORS PIM1, PIM2, PIM3 ABCG2 2980/4885CDC7 141/4885CTNNB1 4214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.